ImClone Systems issues statement regarding Swissmedic approval of Erbitux for the treatment of head and neck cancer.

(From Chemical Business NewsBase - Press Release)

ImClone Systems Inc issued the following statement regarding the approval by Swissmedic, the Swiss agency for therapeutic products, of Erbitux (cetuximab), an IgG1 monoclonal antibody, in combination with radiation in the treatment of patients with previously untreated, advanced squamous cell carcinoma of the head and neck. This approval gives doctors in Switzerland a first-of-its-kind treatment option in a tumour type that has seen no new modalities of treatment in thirty years. ImClone Systems and Merck KGaA will continue to study Erbitux in head and neck cancer, including in combination with chemoradiation, and are …